Bristol-Myers Squibb Co BMY

Stock XNYS Rating as of Oct 1, 2026

$61.15 +0.32 (0.53%)

View Full Chart

As of Oct 2, 2026, 8:00:18 PM Delayed Price Post-Trading: $60.80 −0.35

Company Report

View Archive

Bristol Is Countering a Significant Patent Cliff With a Promising, Diversified Pipeline

Karen Andersen Jul 30, 2026

Adept at partnerships and acquisitions, Bristol-Myers Squibb has built a strong portfolio of drugs and a robust pipeline. This strategy is evident in the acquisition of Celgene, which netted the firm an excellent pipeline and a strong foothold in blood cancer. More recent acquisitions—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat.

Read Analysis

Price vs Fair Value

View History

BMY is trading at a LOCK|vdxT premium.

Price

$61.46

Oct 1, 2026

Fair Value

Feb 5, 2026

Uncertainty

LOCK|>%s$s

1-Star Price: LOCK|.g$
5-Star Price: <X
Economic Moat: LOCK|G@
Capital Allocation: LOCK|SgVC@GG

Bulls Say, Bears Say

Bulls

Bristol is launching innovative drugs in cardiology and neurology, which should have strong sales trajectories, given the high unmet medical need.

Bears

The acquisition of Celgene came shortly before the start of generic competition for that firm's cancer drug Revlimid in 2022, setting up a major growth obstacle over several years, given the planned staggered generic entry.

News

View All

Articles & Videos

Trading Information

Previous Close Price: $60.83
Day Range: $60.24–61.24
52-Week Range: $42.52–68.64
Bid/Ask: $60.75 / $61.21
Shares Outstanding: 2.04B
Market Cap: $124.91B
Volume/Avg: 10M / 11M

Key Statistics

Price/Earnings (Normalized): 9.47
Price/Sales: 2.55
Dividend Yield (Trailing): 4.08%
Dividend Yield (Forward): 4.10%
Dividend Payment Schedule: Feb, May, Aug, Nov
Total Yield: 4.08%

Company Profile

Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Sector: Healthcare
Industry: Drug Manufacturers - General
Stock Style Box: Large Value
Total Number of Employees: 32,500
Website: https://www.bms.com

Competitors

Valuation

Metric	BMY	MRK	GSK
Price/Earnings (Normalized)	9.47	44.80	11.62
Price/Book Value	5.62	8.47	4.04
Price/Sales	2.55	5.36	2.16
Price/Cash Flow	8.46	16.10	9.25

Price/Earnings

BMY

MRK

GSK

Financial Strength

Metric	BMY	MRK	GSK
Quick Ratio	1.29	0.71	0.52
Current Ratio	1.53	1.32	0.82
Interest Coverage	7.88	4.28	9.51

Quick Ratio

BMY

MRK

GSK

Profitability

Metric	BMY	MRK	GSK
Return on Assets (Normalized)	14.59%	6.27%	11.66%
Return on Equity (Normalized)	68.67%	16.68%	42.98%
Return on Invested Capital (Normalized)	21.69%	9.82%	22.63%

Return on Assets

BMY

MRK

GSK

Drug Manufacturers - General Industry Comparables

Screen With Investor

Name	Capital Allocation	Economic Moat	Market Cap
Eli Lilly and Co LLY	LOCK\|mKTB$wF?	LOCK\|p&	$1T
Johnson & Johnson JNJ	LOCK\|?S@^@@	LOCK\|>kn	$623B
AbbVie Inc ABBV	LOCK\|B^jy^W^	LOCK\|@k	$459B
Merck & Co Inc MRK	LOCK\|SpZH^X#	LOCK\|T$?	$355B
Roche Holding AG ADR RHHBY	LOCK\|#@CpW&v^	LOCK\|fn	$334B
Novartis AG ADR NVS	LOCK\|GB<P<L&	LOCK\|Jtx	$268B
AstraZeneca PLC AZN	LOCK\|#n?$%Bw<	LOCK\|wT	$248B
Amgen Inc AMGN	LOCK\|yQ!@%Lp	LOCK\|Bc	$220B
Gilead Sciences Inc GILD	LOCK\|N??PMm	LOCK\|^S^	$183B
Novo Nordisk AS ADR NVO	LOCK\|^NjW&kW	LOCK\|g^<	$167B

Bristol-Myers Squibb Co BMY

Company Report

Bristol Is Countering a Significant Patent Cliff With a Promising, Diversified Pipeline

Price vs Fair Value

Bulls Say, Bears Say

Bulls

Bears

News

Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement

Bristol Myers Squibb Says FDA Approves Heart Disease Treatment Camzyos for Pediatric Patients

U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*

Novo Inks Weight-Loss Licensing Deal With Hengrui Pharma

Care Within Reach: How the Bristol Myers Squibb Foundation Is Strengthening Health Systems Across Africa

Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma

Leveraging Brazil's Health Networks for Early Lung Cancer Detection

Transforming Lung Cancer Care & Early Detection in Tanzania

Articles & Videos

AstraZeneca and Bristol-Myers Squibb: Megamerger Reports Leave Us Scratching Our Heads

The Best Companies to Own

As Biopharma Turns to China, ESG Risks and Geopolitics Remain in Focus

3 Stocks to Invest In to Rebalance Your Portfolio

5 Stocks to Buy Before They’re Not Undervalued Anymore

Best Innovative Companies to Own: 2026 Edition

As Tech Struggles, Dividend Stocks Step Back Into the Limelight

Markets Brief: What’s Clipping Microsoft Stock, Pharma Earnings and Jobs Report on Deck

2 Top Blue-Chip Stocks to Buy and Hold in 2026

Trading Information

Key Statistics

Company Profile

Competitors

Valuation

Financial Strength

Profitability

Drug Manufacturers - General Industry Comparables

Sponsor Center

What We Do

Company

Get Help